- 2 days ago
- 4 min
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
The meeting date assigned by the FDA is June 9, 2024
- 6 days ago
- 3 min
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:...
- Apr 16
- 5 min
Golden Goliath Corporate Update
The main focus will be on the 100% owned Wish Ore Gold property located just off the Trans-Canada highway 60 km north of Sault Ste. Marie..